Target Binding Site Detail
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T16538 | Target Info | |||
Target Name | EGFR T790M mutant (EGFR T790M) | ||||
Synonyms | Receptor tyrosine-protein kinase erbB-1 T790M mutant; Proto-oncogene c-ErbB-1 T790M mutant; HER1 T790M mutant; Epidermal growth factor receptor T790M mutant; ERBB1 T790M mutant; ERBB T790M mutant | ||||
Target Type | Successful Target | ||||
Gene Name | EGFR | ||||
Biochemical Class | Kinase | ||||
UniProt ID |
Ligand General Information | Top | ||||
---|---|---|---|---|---|
Ligand Name | N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]propanamide | Ligand Info | |||
Canonical SMILES | CCC(=O)NC1=CC(=C(C=C1N(C)CCN(C)C)OC)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C | ||||
InChI | 1S/C28H35N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h8-13,16-18H,7,14-15H2,1-6H3,(H,30,36)(H,29,31,32) | ||||
InChIKey | UHTBXBRYOKJTAN-UHFFFAOYSA-N | ||||
PubChem Compound ID | 71244256 |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
PDB ID: 6Z4B Crystal Structure of EGFR-T790M/V948R in Complex with Osimertinib and EAI045 | ||||||
Method | X-ray diffraction | Resolution | 2.50 Å | Mutation | Yes | [1] |
PDB Sequence |
NQALLRILKE
709 TEFKKIKVLG719 SGAFGTVYKG729 LWIPEGEKVK739 IPVAIKELRE749 ATSPKANKEI 759 LDEAYVMASV769 DNPHVCRLLG779 ICLTSTVQLI789 MQLMPFGCLL799 DYVREHKDNI 809 GSQYLLNWCV819 QIAKGMNYLE829 DRRLVHRDLA839 ARNVLVKTPQ849 HVKITDFGLA 859 KLLKVPIKWM881 ALESILHRIY891 THQSDVWSYG901 VTVWELMTFG911 SKPYDGIPAS 921 EISSILEKGE931 RLPQPPICTI941 DVYMIMRKCW951 MIDADSRPKF961 RELIIEFSKM 971 ARDPQRYLVI981 Q
|
|||||
|
VAL717
4.205
LEU718
3.015
GLY719
3.491
SER720
3.871
GLY721
4.423
VAL726
3.456
ALA743
3.467
LYS745
4.402
MET790
3.576
GLN791
3.720
LEU792
3.645
MET793
3.224
|
|||||
PDB ID: 6XL4 EGFR(T790M/V948R) in complex with AZD9291 and DDC4002 | ||||||
Method | X-ray diffraction | Resolution | 2.06 Å | Mutation | Yes | [2] |
PDB Sequence |
NQALLRILKE
709 TEFKKIKVLG719 SGAFGTVYKG729 LWIPEGEKVK739 IPVAIKELRE749 ATSPKANKEI 759 LDEAYVMASV769 DNPHVCRLLG779 ICLTSTVQLI789 MQLMPFGCLL799 DYVREHKDNI 809 GSQYLLNWCV819 QIAKGMNYLE829 DRRLVHRDLA839 ARNVLVKTPQ849 HVKITDFGLA 859 KVPIKWMALE884 SILHRIYTHQ894 SDVWSYGVTV904 WELMTFGSKP914 YDGIPASEIS 924 SILEKGERLP934 QPPICTIDVY944 MIMRKCWMID954 ADSRPKFREL964 IIEFSKMARD 974 PQRYLVIQGD984 ERMHLPSPTD994 SNFYRALMDE1004 EDM
|
|||||
|
LEU718
3.347
GLY719
3.948
PHE723
3.812
VAL726
3.530
ALA743
3.492
LYS745
4.908
MET790
3.492
GLN791
3.135
LEU792
3.606
MET793
2.633
|
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. ACS Med Chem Lett. 2020 Nov 5;11(12):2484-2490. | ||||
REF 2 | Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Nat Commun. 2022 May 9;13(1):2530. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.